Primary Biliary Cholangitis clinical trials at UCSF
1 research study open to eligible people
Primary biliary cholangitis is a chronic disease causing the liver ducts to become inflamed and damaged. UCSF is running trials to test the effectiveness of Seladelpar on liver health in patients with this condition and compensated cirrhosis. The trials examine how the medication impacts clinical outcomes over time.
Showing trials for
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
open to eligible people ages 18 years and up
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
San Francisco, California and other locations
Last updated: